<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35840315</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2373-2822</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>eNeuro</Title><ISOAbbreviation>eNeuro</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein A1 Enhances Endothelial Cell Survival in an <i>In Vitro</i> Model of ALS.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ENEURO.0140-22.2022</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1523/ENEURO.0140-22.2022</ELocationID><Abstract><AbstractText>Altered lipoprotein metabolism is considered a pathogenic component of amyotrophic lateral sclerosis (ALS). Apolipoprotein A1 (ApoA1), a major high-density lipoprotein (HDL) protein, is associated with prevention of vascular damage. However, ApoA1's effects on damaged endothelium in ALS are unknown. This study aimed to determine therapeutic potential of ApoA1 for endothelial cell (EC) repair under a pathologic condition reminiscent of ALS. We performed <i>in vitro</i> studies using mouse brain ECs (mBECs) exposed to plasma from symptomatic G93A SOD1 mice. Dosage effects of ApoA1, including inhibition of the phosphoinoside 3-kinase (PI3K)/Akt signaling pathway and integration of ApoA1 into mBECs were examined. Also, human bone marrow-derived endothelial progenitor cells (hBM-EPCs) and mBECs were co-cultured without cell contact to establish therapeutic mechanism of hBM-EPC transplantation. Results showed that ApoA1 significantly reduced mBEC death via the PI3K/Akt downstream signaling pathway. Also, ApoA1 was incorporated into mBECs as confirmed by blocked ApoA1 cellular integration. Co-culture system provided evidence that ApoA1 was secreted by hBM-EPCs and incorporated into injured mBECs. Thus, our study findings provide important evidence for ApoA1 as a potential novel therapeutic for endothelium protection in ALS. This <i>in vitro</i> study lays the groundwork for further <i>in vivo</i> research to fully determine therapeutic effects of ApoA1 in ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Garbuzova-Davis et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garbuzova-Davis</LastName><ForeName>Svitlana</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5816-0937</Identifier><AffiliationInfo><Affiliation>Center of Excellence for Aging &amp; Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, FL 33613 sgarbuzo@usf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery and Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, FL 33613.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Physiology, University of South Florida, Morsani College of Medicine, Tampa, FL 33613.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, University of South Florida, Morsani College of Medicine, Tampa, FL 33613.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willing</LastName><ForeName>Alison E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Center of Excellence for Aging &amp; Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, FL 33613.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery and Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, FL 33613.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Physiology, University of South Florida, Morsani College of Medicine, Tampa, FL 33613.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borlongan</LastName><ForeName>Cesario V</ForeName><Initials>CV</Initials><AffiliationInfo><Affiliation>Center of Excellence for Aging &amp; Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, FL 33613.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery and Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, FL 33613.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS090962</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>eNeuro</MedlineTA><NlmUniqueID>101647362</NlmUniqueID><ISSNLinking>2373-2822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016632">Apolipoprotein A-I</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016632" MajorTopicYN="N">Apolipoprotein A-I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004727" MajorTopicYN="N">Endothelium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS SOD1 mice</Keyword><Keyword MajorTopicYN="N">LIVE/DEAD cell viability assay</Keyword><Keyword MajorTopicYN="N">apolipoprotein A1</Keyword><Keyword MajorTopicYN="N">endothelial cell</Keyword><Keyword MajorTopicYN="N">in vitro</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>15</Day><Hour>21</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35840315</ArticleId><ArticleId IdType="pmc">PMC9337612</ArticleId><ArticleId IdType="doi">10.1523/ENEURO.0140-22.2022</ArticleId><ArticleId IdType="pii">ENEURO.0140-22.2022</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Armstrong RA (2019) Risk factors for Alzheimer&#x2019;s disease. Folia Neuropathol 57:87&#x2013;105. 10.5114/fn.2019.85929</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/fn.2019.85929</ArticleId><ArticleId IdType="pubmed">31556570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Highton-Williamson E, Caga J, Thornton N, Ramsey E, Zoing M, Kim WS, Halliday GM, Piguet O, Hodges JR, Farooqi IS, Kiernan MC (2018) Lipid metabolism and survival across the frontotemporal dementia-amyotrophic lateral sclerosis spectrum: relationships to eating behavior and cognition. J Alzheimers Dis 61:773&#x2013;783. 10.3233/JAD-170660</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170660</ArticleId><ArticleId IdType="pubmed">29254092</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachus R, Bader S, Gessner R, Ludolph AC (1997) Lack of association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease. Ann Neurol 41:417. 10.1002/ana.410410326</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410326</ArticleId><ArticleId IdType="pubmed">9066369</ArticleId></ArticleIdList></Reference><Reference><Citation>Benn M (2009) Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. Atherosclerosis 206:17&#x2013;30. 10.1016/j.atherosclerosis.2009.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2009.01.004</ArticleId><ArticleId IdType="pubmed">19200547</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A, Pagani M, Brunetti M, Barberis M, Iazzolino B, Ilardi A, Cammarosano S, Manera U, Moglia C, Calvo A, Cistaro A, Chi&#xf2; A (2019) Correlation between apolipoprotein E genotype and brain metabolism in amyotrophic lateral sclerosis. Eur J Neurol 26:306&#x2013;312. 10.1111/ene.13812</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13812</ArticleId><ArticleId IdType="pubmed">30240096</ArticleId></ArticleIdList></Reference><Reference><Citation>Castaing-Berthou A, Malet N, Radojkovic C, Cabou C, Gayral S, Martinez LO, Laffargue M (2017) PI3K&#x3b2; plays a key role in apolipoprotein A-I-induced endothelial cell proliferation through activation of the Ecto-F1-ATPase/P2Y1 receptors. Cell Physiol Biochem 42:579&#x2013;593. 10.1159/000477607</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000477607</ArticleId><ArticleId IdType="pubmed">28578353</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves-Filho AB, Pinto IFD, Dantas LS, Xavier AM, Inague A, Faria RL, Medeiros MHG, Glezer I, Yoshinaga MY, Miyamoto S (2019) Alterations in lipid metabolism of spinal cord linked to amyotrophic lateral sclerosis. Sci Rep 9:11642. 10.1038/s41598-019-48059-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48059-7</ArticleId><ArticleId IdType="pmc">PMC6691112</ArticleId><ArticleId IdType="pubmed">31406145</ArticleId></ArticleIdList></Reference><Reference><Citation>Che&#x142;stowska B, Bara&#x144;czyk-Ku&#x17a;ma A, Ku&#x17a;ma-Kozakiewicz M (2021) Dyslipidemia in patients with amyotrophic lateral sclerosis - a case control retrospective study. Amyotroph Lateral Scler Frontotemporal Degener 22:195&#x2013;205. 10.1080/21678421.2020.1832119</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1832119</ArticleId><ArticleId IdType="pubmed">33103950</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Strickland MR, Soranno A, Holtzman DM (2021) Apolipoprotein E: structural insights and links to Alzheimer disease pathogenesis. Neuron 109:205&#x2013;221. 10.1016/j.neuron.2020.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.10.008</ArticleId><ArticleId IdType="pmc">PMC7931158</ArticleId><ArticleId IdType="pubmed">33176118</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Ilardi A, Cavallo E, Moglia C, Mutani R, Palmo A, Galletti R, Marinou K, Papetti L, Mora G (2009) Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology 73:1681&#x2013;1685. 10.1212/WNL.0b013e3181c1df1e</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df1e</ArticleId><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochran BJ, Ong KL, Manandhar B, Rye KA (2021) APOA1: a protein with multiple therapeutic functions. Curr Atheroscler Rep 23:11. 10.1007/s11883-021-00906-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11883-021-00906-7</ArticleId><ArticleId IdType="pubmed">33591433</ArticleId></ArticleIdList></Reference><Reference><Citation>Crivellato E (2011) The role of angiogenic growth factors in organogenesis. Int J Dev Biol 55:365&#x2013;375. 10.1387/ijdb.103214ec</Citation><ArticleIdList><ArticleId IdType="doi">10.1387/ijdb.103214ec</ArticleId><ArticleId IdType="pubmed">21858761</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis AA, Inman CE, Wargel ZM, Dube U, Freeberg BM, Galluppi A, Haines JN, Dhavale DD, Miller R, Choudhury FA, Sullivan PM, Cruchaga C, Perlmutter JS, Ulrich JD, Benitez BA, Kotzbauer PT, Holtzman DM (2020) APOE genotype regulates pathology and disease progression in synucleinopathy. Sci Transl Med 12:eaay3069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289511</ArticleId><ArticleId IdType="pubmed">32024799</ArticleId></ArticleIdList></Reference><Reference><Citation>Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, Bruno S, Bussolati B, Camussi G (2007) Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 110:2440&#x2013;2448. 10.1182/blood-2007-03-078709</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-03-078709</ArticleId><ArticleId IdType="pubmed">17536014</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, Seilhean D, Hauw JJ, Lacomblez L, Loeffler JP, Meininger V (2008) Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70:1004&#x2013;1009. 10.1212/01.wnl.0000285080.70324.27</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrhart J, Sanberg PR, Garbuzova-Davis S (2018) Plasma derived from human umbilical cord blood: potential cell-additive or cell-substitute therapeutic for neurodegenerative diseases. J Cell Mol Med 22:6157&#x2013;6166. 10.1111/jcmm.13898</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.13898</ArticleId><ArticleId IdType="pmc">PMC6237605</ArticleId><ArticleId IdType="pubmed">30334335</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Beltr&#xe1;n LC, Godoy-Corchuelo JM, Losa-Fontangordo M, Williams D, Matias-Guiu J, Corrochano S (2021) A transcriptomic meta-analysis shows lipid metabolism dysregulation as an early pathological mechanism in the spinal cord of SOD1 mice. Int J Mol Sci 22:9553. 10.3390/ijms22179553</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22179553</ArticleId><ArticleId IdType="pmc">PMC8431303</ArticleId><ArticleId IdType="pubmed">34502460</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Xu Z (2008) Mechanisms of action of angiogenin. Acta Biochim Biophys Sin (Shanghai) 40:619&#x2013;624. 10.1111/j.1745-7270.2008.00442.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-7270.2008.00442.x</ArticleId><ArticleId IdType="pubmed">18604453</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Haller E, Saporta S, Kolomey I, Nicosia SV, Sanberg PR (2007a) Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res 1157:126&#x2013;137. 10.1016/j.brainres.2007.04.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.04.044</ArticleId><ArticleId IdType="pubmed">17512910</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett SP, Potter H, Sanberg PR (2007b) Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS One 2:e1205. 10.1371/journal.pone.0001205</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001205</ArticleId><ArticleId IdType="pmc">PMC2075163</ArticleId><ArticleId IdType="pubmed">18030339</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Hernandez-Ontiveros DG, Rodrigues MCO, Haller E, Frisina-Deyo A, Mirtyl S, Sallot S, Saporta S, Borlongan CV, Sanberg PR (2012) Impaired blood-brain/spinal cord barrier in ALS patients. Brain Res 1469:114&#x2013;128. 10.1016/j.brainres.2012.05.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.05.056</ArticleId><ArticleId IdType="pubmed">22750125</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Kurien C, Thomson A, Falco D, Ahmad S, Staffetti J, Steiner G, Abraham S, James G, Mahendrasah A, Sanberg PR, Borlongan CV (2017) Endothelial and astrocytic support by human bone marrow stem cell grafts into symptomatic ALS mice towards blood-spinal cord barrier repair. Sci Rep 7:884. 10.1038/s41598-017-00993-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-00993-0</ArticleId><ArticleId IdType="pmc">PMC5429840</ArticleId><ArticleId IdType="pubmed">28408761</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Ehrhart J, Mustafa H, Llauget A, Boccio KJ, Sanberg PR, Appel SH, Borlongan CV (2019a) Phenotypic characteristics of human bone marrow-derived endothelial progenitor cells in vitro support cell effectiveness for repair of the blood-spinal cord barrier in ALS. Brain Res 1724:146428. 10.1016/j.brainres.2019.146428</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2019.146428</ArticleId><ArticleId IdType="pmc">PMC6779528</ArticleId><ArticleId IdType="pubmed">31493389</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Kurien C, Haller E, Eve DJ, Navarro S, Steiner G, Mahendrasah A, Hailu S, Khatib M, Boccio KJ, Borlongan CV, Van Loveren HR, Appel SH, Sanberg PR (2019b) Human bone marrow endothelial progenitor cell transplantation into symptomatic ALS mice delays disease progression and increases motor neuron survival by repairing blood-spinal cord barrier. Sci Rep 9:5280. 10.1038/s41598-019-41747-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41747-4</ArticleId><ArticleId IdType="pmc">PMC6437219</ArticleId><ArticleId IdType="pubmed">30918315</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Willing AE, Ehrhart J, Wang L, Sanberg PR, Borlongan CV (2020) Cell-free extracellular vesicles derived from human bone marrow endothelial progenitor cells as potential therapeutics for microvascular endothelium restoration in ALS. Neuromolecular Med 22:503&#x2013;516. 10.1007/s12017-020-08607-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-020-08607-1</ArticleId><ArticleId IdType="pmc">PMC7677172</ArticleId><ArticleId IdType="pubmed">32820422</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez De Aguilar JL (2019) Lipid biomarkers for amyotrophic lateral sclerosis. Front Neurol 10:284. 10.3389/fneur.2019.00284</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00284</ArticleId><ArticleId IdType="pmc">PMC6458258</ArticleId><ArticleId IdType="pubmed">31019485</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Pecchi V, Vald&#xe9;s S, Pons V, Honorato P, Martinez LO, Lamperti L, Aguayo C, Radojkovic C (2015) Apolipoprotein A-I enhances proliferation of human endothelial progenitor cells and promotes angiogenesis through the cell surface ATP synthase. Microvasc Res 98:9&#x2013;15. 10.1016/j.mvr.2014.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mvr.2014.11.003</ArticleId><ArticleId IdType="pubmed">25445031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamzic E, Whiting K, Pettengell R (2016) Identification of serum APOA1 and APOC3 as potential biomarkers of aplastic anemia. Clin Med Invest 1:1&#x2013;9. 10.15761/CMI.1000101</Citation><ArticleIdList><ArticleId IdType="doi">10.15761/CMI.1000101</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, Bowser R, Appel SH (2009) Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology 72:1614&#x2013;1616. 10.1212/WNL.0b013e3181a41228</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181a41228</ArticleId><ArticleId IdType="pubmed">19414730</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549&#x2013;580. 10.1124/pr.56.4.3</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.56.4.3</ArticleId><ArticleId IdType="pubmed">15602010</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Chen PC, Poole C (2004) APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 62:2198&#x2013;2202. 10.1212/01.wnl.0000130159.28215.6a</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000130159.28215.6a</ArticleId><ArticleId IdType="pubmed">15210882</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Chen L, Zhan Y, Termorshuizen J, Yin L, Fang F (2020) Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology 94:e1835&#x2013;e1844. 10.1212/WNL.0000000000009322</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009322</ArticleId><ArticleId IdType="pmc">PMC7274849</ArticleId><ArticleId IdType="pubmed">32221024</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson AO, Rahman GA, Long S (2021) Apolipoprotein-AI and AIBP synergetic anti-inflammation as vascular diseases therapy: the new perspective. Mol Cell Biochem 476:3065&#x2013;3078. 10.1007/s11010-020-04037-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-020-04037-6</ArticleId><ArticleId IdType="pubmed">33811580</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeyachandran A, Mertens B, McKissick EA, Mitchell CS (2015) Type I vs. type II cytokine levels as a function of SOD1 G93A mouse amyotrophic lateral sclerosis disease progression. Front Cell Neurosci 9:462. 10.3389/fncel.2015.00462</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00462</ArticleId><ArticleId IdType="pmc">PMC4664727</ArticleId><ArticleId IdType="pubmed">26648846</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao Y, Wu MP (2008) Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine 43:83&#x2013;87. 10.1016/j.cyto.2008.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2008.04.002</ArticleId><ArticleId IdType="pubmed">18501625</ArticleId></ArticleIdList></Reference><Reference><Citation>Joardar A, Manzo E, Zarnescu DC (2017) Metabolic dysregulation in amyotrophic lateral sclerosis: challenges and opportunities. Curr Genet Med Rep 5:108&#x2013;114. 10.1007/s40142-017-0123-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40142-017-0123-8</ArticleId><ArticleId IdType="pmc">PMC5647833</ArticleId><ArticleId IdType="pubmed">29057168</ArticleId></ArticleIdList></Reference><Reference><Citation>Koschinsky ML, Marcovina SM (2004) Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol 15:167&#x2013;174. 10.1097/00041433-200404000-00009</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00041433-200404000-00009</ArticleId><ArticleId IdType="pubmed">15017359</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Dong JB, Wu MP (2008) Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice. Eur J Pharmacol 590:417&#x2013;422. 10.1016/j.ejphar.2008.06.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2008.06.047</ArticleId><ArticleId IdType="pubmed">18593575</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YJ, Hauser MA, Scott WK, Martin ER, Booze MW, Qin XJ, Walter JW, Nance MA, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Goetz CG, Small GW, Mastaglia F, Haines JL, Pericak-Vance MA, Vance JM (2004a) Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology 62:2005&#x2013;2009. 10.1212/01.wnl.0000128089.53030.ac</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000128089.53030.ac</ArticleId><ArticleId IdType="pubmed">15184605</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YJ, Pericak-Vance MA, Haines JL, Siddique N, McKenna-Yasek D, Hung W-Y, Sapp P, Allen CI, Chen W, Hosler B, Saunders AM, Dellefave LM, Brown RH, Siddique T (2004b) Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis. Neurogenetics 5:209&#x2013;213. 10.1007/s10048-004-0193-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-004-0193-0</ArticleId><ArticleId IdType="pubmed">15657798</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Innerarity TL, Rall SC, Weisgraber KH (1984) Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 25:1277&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pubmed">6099394</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Rosi E, Fini N, Fasano A, Raggi S, Fantuzzi AL, Bedogni G (2017) Changes in routine laboratory tests and survival in amyotrophic lateral sclerosis. Neurol Sci 38:2177&#x2013;2182. 10.1007/s10072-017-3138-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-017-3138-8</ArticleId><ArticleId IdType="pubmed">28980128</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Hammar N, Malmstr&#xf6;m H, Ingre C, Jungner I, Ye W, Fang F, Walldius G (2017) Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol 81:718&#x2013;728. 10.1002/ana.24936</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24936</ArticleId><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Mineo C, Deguchi H, Griffin JH, Shaul PW (2006) Endothelial and antithrombotic actions of HDL. Circ Res 98:1352&#x2013;1364. 10.1161/01.RES.0000225982.01988.93</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000225982.01988.93</ArticleId><ArticleId IdType="pubmed">16763172</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki K, Ohta Y, Nagai M, Morimoto N, Kurata T, Takehisa Y, Ikeda Y, Matsuura T, Abe K (2011) Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J Neurosci Res 89:718&#x2013;728. 10.1002/jnr.22594</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22594</ArticleId><ArticleId IdType="pubmed">21337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Mart&#xed;nez L, de la Torre M, Toivonen JM, Zaragoza P, Garc&#xed;a-Redondo A, Calvo AC, Osta R (2019) Circulating cytokines could not be good prognostic biomarkers in a mouse model of amyotrophic lateral sclerosis. Front Immunol 10:801. 10.3389/fimmu.2019.00801</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00801</ArticleId><ArticleId IdType="pmc">PMC6473074</ArticleId><ArticleId IdType="pubmed">31031774</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita S (2016) Metabolism and modification of apolipoprotein B-containing lipoproteins involved in dyslipidemia and atherosclerosis. Biol Pharm Bull 39:1&#x2013;24. 10.1248/bpb.b15-00716</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.b15-00716</ArticleId><ArticleId IdType="pubmed">26725424</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulard B, Sefiani A, Laamri A, Malafosse A, Camu W (1996) Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis. J Neurol Sci 139:34&#x2013;37. 10.1016/0022-510X(96)00085-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(96)00085-8</ArticleId><ArticleId IdType="pubmed">8899655</ArticleId></ArticleIdList></Reference><Reference><Citation>Mui S, Rebeck GW, McKenna-Yasek D, Hyman BT, Brown RH (1995) Apolipoprotein E epsilon 4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. Ann Neurol 38:460&#x2013;463. 10.1002/ana.410380318</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410380318</ArticleId><ArticleId IdType="pubmed">7668834</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz SS, Garner B, Ooi L (2019) Understanding the role of ApoE fragments in Alzheimer&#x2019;s disease. Neurochem Res 44:1297&#x2013;1305. 10.1007/s11064-018-2629-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-018-2629-1</ArticleId><ArticleId IdType="pubmed">30225748</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen H, Lee JY, Sanberg PR, Napoli E, Borlongan CV (2019) Eye opener in stroke. Stroke 50:2197&#x2013;2206. 10.1161/STROKEAHA.119.025249</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.119.025249</ArticleId><ArticleId IdType="pmc">PMC6650274</ArticleId><ArticleId IdType="pubmed">31242827</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills A-M (2011) Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 44:20&#x2013;24. 10.1002/mus.22114</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22114</ArticleId><ArticleId IdType="pmc">PMC4441750</ArticleId><ArticleId IdType="pubmed">21607987</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan B, Kong J, Jin J, Kong J, He Y, Dong S, Ji L, Liu D, He D, Kong L, Jin DK, Willard B, Pennathur S, Zheng L (2016) A novel anti-inflammatory mechanism of high density lipoprotein through up-regulating annexin A1 in vascular endothelial cells. Biochim Biophys Acta 1861:501&#x2013;512. 10.1016/j.bbalip.2016.03.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2016.03.022</ArticleId><ArticleId IdType="pubmed">27012521</ArticleId></ArticleIdList></Reference><Reference><Citation>Puranik R, Bao S, Nobecourt E, Nicholls SJ, Dusting GJ, Barter PJ, Celermajer DS, Rye K-A (2008) Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis 196:240&#x2013;247. 10.1016/j.atherosclerosis.2007.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2007.05.008</ArticleId><ArticleId IdType="pubmed">17586510</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ (2015) Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: insights from the olesoxime clinical trial. Amyotroph Lateral Scler Frontotemporal Degener 16:478&#x2013;484. 10.3109/21678421.2015.1062517</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1062517</ArticleId><ArticleId IdType="pubmed">26161993</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaud J, Martinoli M-G (2016) Development of an insert co-culture system of two cellular types in the absence of cell-cell contact. J Vis Exp (113). doi: 10.3791/54356.10.3791/54356</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/54356</ArticleId><ArticleId IdType="pubmed">27500972</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert J, Osto E, von Eckardstein A (2021) The endothelium is both a target and a barrier of HDL&#x2019;s protective functions. Cells 10:1041. 10.3390/cells10051041</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10051041</ArticleId><ArticleId IdType="pmc">PMC8146309</ArticleId><ArticleId IdType="pubmed">33924941</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C, Bergstrom G (2014) Apolipoprotein B and apolipopotein A-I in vascular risk prediction - a review. Curr Pharm Des 20:6289&#x2013;6298. 10.2174/1381612820666140620121828</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612820666140620121828</ArticleId><ArticleId IdType="pubmed">24953398</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Das S, Hyman BT (2021) APOE and Alzheimer&#x2019;s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol 20:68&#x2013;80. 10.1016/S1474-4422(20)30412-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30412-9</ArticleId><ArticleId IdType="pmc">PMC8096522</ArticleId><ArticleId IdType="pubmed">33340485</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah PK, Nilsson J, Kaul S, Fishbein MC, Ageland H, Hamsten A, Johansson J, Karpe F, Cercek B (1998) Effects of recombinant apolipoprotein A-I(milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97:780&#x2013;785. 10.1161/01.CIR.97.8.780</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.97.8.780</ArticleId><ArticleId IdType="pubmed">9498542</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah PK, Yano J, Reyes O, Chyu KY, Kaul S, Bisgaier CL, Drake S, Cercek B (2001) High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 103:3047&#x2013;3050. 10.1161/hc2501.092494</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hc2501.092494</ArticleId><ArticleId IdType="pubmed">11425766</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddique T, Pericak-Vance MA, Caliendo J, Hong ST, Hung WY, Kaplan J, McKenna-Yasek D, Rimmler JB, Sapp P, Saunders AM, Scott WK, Siddique N, Haines JL, Brown RH (1998) Lack of association between apolipoprotein E genotype and sporadic amyotrophic lateral sclerosis. Neurogenetics 1:213&#x2013;216. 10.1007/s100480050031</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s100480050031</ArticleId><ArticleId IdType="pubmed">10737125</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JD (2010) Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Curr Opin Investig Drugs 11:989&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074469</ArticleId><ArticleId IdType="pubmed">20730693</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson D, Lagerstedt JO, Nilsson B-O, Del Giudice R (2017) Apolipoprotein A-I attenuates LL-37-induced endothelial cell cytotoxicity. Biochem Biophys Res Commun 493:71&#x2013;76. 10.1016/j.bbrc.2017.09.072</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2017.09.072</ArticleId><ArticleId IdType="pubmed">28919413</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabet F, Rye K-A (2009) High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond) 116:87&#x2013;98. 10.1042/CS20080106</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20080106</ArticleId><ArticleId IdType="pubmed">19076062</ArticleId></ArticleIdList></Reference><Reference><Citation>Tammela T, Enholm B, Alitalo K, Paavonen K (2005) The biology of vascular endothelial growth factors. Cardiovasc Res 65:550&#x2013;563. 10.1016/j.cardiores.2004.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardiores.2004.12.002</ArticleId><ArticleId IdType="pubmed">15664381</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur K, Tiwari A, Sharma K, Modgil S, Khosla R, Anand A (2020) Angiogenesis-centered molecular cross-talk in amyotrophic lateral sclerosis survival: mechanistic insights. Crit Rev Eukaryot Gene Expr 30:137&#x2013;151. 10.1615/CritRevEukaryotGeneExpr.2020031020</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/CritRevEukaryotGeneExpr.2020031020</ArticleId><ArticleId IdType="pubmed">32558493</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilatos D, Fotakis P, Valanti E, Sanoudou D, Zannis V, Kardassis D (2018) HDL-apoA-I induces the expression of angiopoietin like 4 (ANGPTL4) in endothelial cells via a PI3K/AKT/FOXO1 signaling pathway. Metabolism 87:36&#x2013;47. 10.1016/j.metabol.2018.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2018.06.002</ArticleId><ArticleId IdType="pubmed">29928895</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandekeere S, Dewerchin M, Carmeliet P (2015) Angiogenesis revisited: an overlooked role of endothelial cell metabolism in vessel sprouting. Microcirculation 22:509&#x2013;517. 10.1111/micc.12229</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/micc.12229</ArticleId><ArticleId IdType="pubmed">26250801</ArticleId></ArticleIdList></Reference><Reference><Citation>Walldius G (2012) The apoB/apoA-1 ratio is a strong predictor of cardiovascular risk. In: Lipoproteins: role in health and diseases, pp 95&#x2013;148. Rijeka: InTech.</Citation></Reference><Reference><Citation>Walldius G, Jungner I (2006) The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy&#x2013;a review of the evidence. J Intern Med 259:493&#x2013;519. 10.1111/j.1365-2796.2006.01643.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2006.01643.x</ArticleId><ArticleId IdType="pubmed">16629855</ArticleId></ArticleIdList></Reference><Reference><Citation>Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD (2004) The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 42:1355&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">15576296</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Xu H, Shi Y, Nandedkar S, Zhang H, Gao H, Feroah T, Weihrauch D, Schulte ML, Jones DW, Jarzembowski J, Sorci-Thomas M, Pritchard KA (2010) Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J Lipid Res 51:2560&#x2013;2570. 10.1194/jlr.M004549</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M004549</ArticleId><ArticleId IdType="pmc">PMC2918439</ArticleId><ArticleId IdType="pubmed">20498409</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Agerberth B, L&#xf6;thgren A, Almstedt A, Johansson J (1998) Apolipoprotein A-I binds and inhibits the human antibacterial/cytotoxic peptide LL-37. J Biol Chem 273:33115&#x2013;33118. 10.1074/jbc.273.50.33115</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.50.33115</ArticleId><ArticleId IdType="pubmed">9837875</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Sullivan JS, Henkel JS, Appel SH, Zlokovic BV (2013) Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol 125:111&#x2013;120. 10.1007/s00401-012-1039-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1039-8</ArticleId><ArticleId IdType="pmc">PMC3535352</ArticleId><ArticleId IdType="pubmed">22941226</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan YJ, Li Y, Lou B, Wu M (2006) Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice. Life Sci 79:210&#x2013;215. 10.1016/j.lfs.2006.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2006.02.011</ArticleId><ArticleId IdType="pubmed">16574162</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>